Company
Cambrian Biopharma
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
What it is
Cambrian Biopharma (founded 2019) operates a portfolio of biotech subsidiaries each targeting a specific hallmark of aging. The model is similar to Juvenescence and Life Biosciences but with tighter operational integration — subsidiaries share R&D, clinical, and regulatory infrastructure.
Subsidiary programmes (publicly disclosed)
- Solanum Biosciences: senescence-focused.
- Verdure Bio: cellular reprogramming.
- Nirogy Therapeutics: monoamine-transporter modulation for metabolic disease.
- Tornado Therapeutics: ferroptosis programmes.
- Several others.
Lead clinical assets
A first-in-human readout of one Cambrian-subsidiary asset is expected to provide the first proof-of-concept for the portfolio.
Funding
Series B round in 2022 brought total funding to ~$160M.
Related entries
Hallmarks of aging, Juvenescence, Life Biosciences, Cellular senescence.